Andexanet: Effectively Reversing Anticoagulation

Giuseppe Lippi; Fabian Sanchis-Gomar; Emmanuel J Favaloro

doi:10.1016/j.tips.2016.03.002

Andexanet: Effectively Reversing Anticoagulation

Trends Pharmacol Sci. 2016 Jun;37(6):413-414. doi: 10.1016/j.tips.2016.03.002. Epub 2016 Apr 2.

Authors

Giuseppe Lippi¹, Fabian Sanchis-Gomar², Emmanuel J Favaloro³

Affiliations

¹ Section of Clinical Biochemistry, University of Verona, Verona, Italy.
² Research Institute of Hospital 12 de Octubre ("i+12"), Madrid, Spain. Electronic address: fabian.sanchis@uv.es.
³ Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Pathology West, NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia.

PMID: 27048885
DOI: 10.1016/j.tips.2016.03.002

Abstract

Despite direct oral anticoagulants becoming a mainstay of anticoagulant therapy, the effective, timely, and safe reversal of their anticoagulant effect remains challenging. Emerging evidence attests that andexanet, a recombinant and inactive variant of native factor X (FXa), competitively inhibits and counteracts the anticoagulant effect of many inhibitors of native activated FXa.

Keywords: Anticoagulants; andexanet; antidote; apixaban; rivaroxaban.

MeSH terms

Administration, Oral
Anticoagulants / adverse effects*
Antidotes / pharmacology*
Blood Coagulation / drug effects
Factor Xa / pharmacology*
Humans
Recombinant Proteins / pharmacology*

Substances

Anticoagulants
Antidotes
PRT064445
Recombinant Proteins
Factor Xa